AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug/ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin i
Ro-23-9424 is a dual-action cephalosporin with a fleroxacin esterified at the 3' position and aminothiazolylmethoxyimino-type side chain at the 7 position. Ro-23-9424 has broad and potent antibacterial activity in vitro and in vivo.
Flumequine-13C3 is intended for use as an internal standard for the quantification of flumequine by GC- or LC-MS. Flumequine (T1060) is a fluoroquinolone antibiotic.1It is active againstS. aureus,S. pyogenes,B. subtilis,E. coli,P. aeruginosa,S. faecalis,andK. pneumoniae (MICs = 1-100 μg/ml). Flumequine (T1060) is also active against field isolates of B. hyodysenteriae (MICs = 6.25-200 μg/ml).2It inhibits DNA gyrase,disrupting supercoiling of bacterial DNA to block transcription and replication.3
Antibacterial agent 94 (compound 5b) is a highly effective antibacterial agent that demonstrates strong activity against various bacterial strains. Notably, Antibacterial Agent 94 is capable of eradicating MRSA persisters, highlighting its potential as a therapeutic solution. Its mechanism of action involves interference with the bacterial membrane and disruption of the phosphatidylglycerol (PG) synthesis pathway [1].